PTAB Ruling Challenges AbbVie’s Imbruvica Patent, Shifts Cancer Drug Market Dynamics

The Patent Trial and Appeal Board (PTAB) has invalidated claims in a patent held by AbbVie’s Pharmacyclics unit concerning the cancer drug Imbruvica. This decision emerges as part of an ongoing intellectual property dispute with BeiGene. The invalidation of the patent claims could impact the strategic positioning of both AbbVie and BeiGene regarding cancer drug market share and exclusivity. For further details, visit Law360.